Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   

Oliena Studio

Stroke and language recovery: 9000+ videos

EspañolItalianoSarduEnglish | PDF+

  Autoimmune Disorders

  Free Subscription


1 BMC Neurol
2 Brain
1 Curr Opin Immunol
2 Curr Treat Options Neurol
3 J Autoimmun
2 J Immunol
1 J Neurol
2 J Rheumatol
3 Mult Scler
3 N Engl J Med
1 PLoS Genet
1 PLoS One
1 Thyroid

  Retrieve available abstracts of this week’s articles:
HTML format
Text format
Single Articles

    BMC Neurol

  1. MAGLIOZZI R, Marastoni D, Rossi S, Castellaro M, et al
    Increase of CSF inflammatory profile in a case of highly active multiple sclerosis.
    BMC Neurol. 2019;19:231.
    PubMed     Text format     Abstract available


  2. NUTMA E, Stephenson JA, Gorter RP, de Bruin J, et al
    A quantitative neuropathological assessment of translocator protein expression in multiple sclerosis.
    Brain. 2019 Oct 3. pii: 5580333. doi: 10.1093.
    PubMed     Text format     Abstract available

  3. KARAKAYA M, Wirth B
    Hereditary nodo-paranodopathies: genomic variants, not just autoantibodies, hit the protein.
    Brain. 2019;142:2895-2897.
    PubMed     Text format    

    Curr Opin Immunol

  4. ELLEBRECHT CT, Lundgren DK, Payne AS
    On the mark: genetically engineered immunotherapies for autoimmunity.
    Curr Opin Immunol. 2019;61:69-73.
    PubMed     Text format     Abstract available

    Curr Treat Options Neurol

  5. MACARON G, Feng J, Moodley M, Rensel M, et al
    Newer Treatment Approaches in Pediatric-Onset Multiple Sclerosis.
    Curr Treat Options Neurol. 2019;21:50.
    PubMed     Text format     Abstract available

  6. FISHER K, Shah V
    Pediatric Ocular Myasthenia Gravis.
    Curr Treat Options Neurol. 2019;21:46.
    PubMed     Text format     Abstract available

    J Autoimmun

  7. YE J, Richardson TG, McArdle WL, Relton CL, et al
    Identification of loci where DNA methylation potentially mediates genetic risk of type 1 diabetes.
    J Autoimmun. 2018;93:66-75.
    PubMed     Text format     Abstract available

  8. LOMBARDI A, Tsomos E, Hammerstad SS, Tomer Y, et al
    Interferon alpha: The key trigger of type 1 diabetes.
    J Autoimmun. 2018 Aug 13. pii: S0896-8411(18)30323.
    PubMed     Text format     Abstract available

  9. HUANG C, Zhu HX, Yao Y, Bian ZH, et al
    Immune checkpoint molecules. Possible future therapeutic implications in autoimmune diseases.
    J Autoimmun. 2019 Sep 26:102333. doi: 10.1016/j.jaut.2019.102333.
    PubMed     Text format     Abstract available

    J Immunol

  10. ANDREAS N, Potthast M, Geiselhoringer AL, Garg G, et al
    RelB Deficiency in Dendritic Cells Protects from Autoimmune Inflammation Due to Spontaneous Accumulation of Tissue T Regulatory Cells.
    J Immunol. 2019 Oct 2. pii: jimmunol.1801530. doi: 10.4049/jimmunol.1801530.
    PubMed     Text format     Abstract available

  11. DROHOMYRECKY PC, Doroshenko ER, Akkermann R, Moshkova M, et al
    Peroxisome Proliferator-Activated Receptor-delta Acts within Peripheral Myeloid Cells to Limit Th Cell Priming during Experimental Autoimmune Encephalomyelitis.
    J Immunol. 2019 Oct 2. pii: jimmunol.1801200. doi: 10.4049/jimmunol.1801200.
    PubMed     Text format     Abstract available

    J Neurol

  12. MARGONI M, Rinaldi F, Riccardi A, Franciotta S, et al
    No evidence of disease activity including cognition (NEDA-3 plus) in naive pediatric multiple sclerosis patients treated with natalizumab.
    J Neurol. 2019 Sep 27. pii: 10.1007/s00415-019-09554.
    PubMed     Text format     Abstract available

    J Rheumatol

  13. COUTURE P, Bachmeyer C, Monfort JB
    Koebner Phenomenon in Dermatomyositis after Subcutaneous Methotrexate Injections.
    J Rheumatol. 2019;46:1350.
    PubMed     Text format    

  14. MORAND EF, Golder V
    Treat-to-target Endpoint Definitions in Systemic Lupus Erythematosus: More Is Less?
    J Rheumatol. 2019;46:1256-1258.
    PubMed     Text format    

    Mult Scler

  15. IGHANI M, Jonas S, Izbudak I, Choi S, et al
    No association between cortical lesions and leptomeningeal enhancement on 7-Tesla MRI in multiple sclerosis.
    Mult Scler. 2019 Oct 1:1352458519876037. doi: 10.1177/1352458519876037.
    PubMed     Text format     Abstract available

  16. GRYTTEN N, Myhr KM, Celius EG, Benjaminsen E, et al
    Risk of cancer among multiple sclerosis patients, siblings, and population controls: A prospective cohort study.
    Mult Scler. 2019 Oct 1:1352458519877244. doi: 10.1177/1352458519877244.
    PubMed     Text format     Abstract available

  17. ZECCA C, Bovis F, Novi G, Capobianco M, et al
    Treatment of multiple sclerosis with rituximab: A multicentric Italian-Swiss experience.
    Mult Scler. 2019 Oct 1:1352458519872889. doi: 10.1177/1352458519872889.
    PubMed     Text format     Abstract available

    N Engl J Med

  18. TAZAWA R, Ueda T, Abe M, Tatsumi K, et al
    Inhaled GM-CSF for Pulmonary Alveolar Proteinosis.
    N Engl J Med. 2019;381:923-932.
    PubMed     Text format     Abstract available

  19. COOPER N, Ghanima W
    Immune Thrombocytopenia.
    N Engl J Med. 2019;381:945-955.
    PubMed     Text format    

  20. SHARMA K, Patel A
    Livedo Reticularis in Cold Agglutinin Disease.
    N Engl J Med. 2019;381:e27.
    PubMed     Text format    

    PLoS Genet

  21. MOLINEROS JE, Looger LL, Kim K, Okada Y, et al
    Amino acid signatures of HLA Class-I and II molecules are strongly associated with SLE susceptibility and autoantibody production in Eastern Asians.
    PLoS Genet. 2019;15:e1008092.
    PubMed     Text format     Abstract available

    PLoS One

  22. ROONEY NJ, Guest CM, Swanson LCM, Morant SV, et al
    How effective are trained dogs at alerting their owners to changes in blood glycaemic levels?: Variations in performance of glycaemia alert dogs.
    PLoS One. 2019;14:e0210092.
    PubMed     Text format     Abstract available


  23. SUZUKI N, Noh JY, Hiruma M, Kawaguchi A, et al
    Analysis of Antithyroid Drug-Induced Severe Liver Injury in 18,558 Newly Diagnosed Patients with Graves' Disease in Japan.
    Thyroid. 2019 Oct 1. doi: 10.1089/thy.2019.0045.
    PubMed     Text format     Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Autoimmune Disorders is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.